Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 2/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422771 | 0.93 | SLC18A3 (0.45) | SLC18A3IP6K1GRIN2BDRD3DRD2 | |
| SCHEMBL421387 | 0.88 | ALDH1A1 (0.40) | GRIN2BDRD3DRD2HTR6CYP2D6 | |
| SCHEMBL421170 | 0.87 | ALDH1A1 (0.42) | DRD3DRD2HTR6CYP2D6CYP2C19 | |
| SCHEMBL421939 | 0.83 | OPRM1 (0.41) | HRH3KHK | |
| SCHEMBL422484 | 0.83 | KDM4E (0.42) | DRD3DRD2HTR6HRH3KHK | |
| SCHEMBL420850 | 0.82 | HRH3 (0.39) | GRIN2BDRD3DRD2HTR6HRH3 | |
| SCHEMBL419554 | 0.82 | HRH3 (0.44) | HRH3 | |
| SCHEMBL421357 | 0.82 | RAB9A (0.48) | GRIN2BDRD3DRD2HTR6CYP2D6 | |
| SCHEMBL3792851 | 0.82 | TMEM97 (0.40) | DRD3DRD2HTR6CYP2D6CYP2C19 | |
| SCHEMBL420265 | 0.81 | IP6K1 (0.41) | IP6K1DRD3DRD2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2396327-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | SLC18A3 19/4885IP6K1 670/4885GRIN2B 57/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | SLC18A3 19/4885IP6K1 670/4885GRIN2B 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.